Denali Therapeutics Inc.
161 Oyster Point Boulevard
South San Francisco
California
94080
United States
Website: http://www.denalitherapeutics.com/
Email: contact@dnli.com
128 articles with Denali Therapeutics Inc.
-
Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN)
11/17/2021
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that its strategic partner Takeda Pharmaceutical Company Limited (“Takeda”) has exercised an option, pursuant to an existing collaboration agreement between the two companies, to co-develop and co-commercialize DNL593 (PTV:PGRN).
-
Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
11/4/2021
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases, reported financial results for the third quarter ended September 30, 2021, and provided business highlights.
-
Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development of Novel ASO Therapeutics in the Field of CNS Diseases
10/26/2021
Companies broaden use of Secarna's industry-leading ASO discovery and development platform LNAplus TM and Denali's blood-brain barrier Transport Vehicle (TV) technology
-
Denali Therapeutics reported positive Phase I data and regulatory progress for two therapeutics for ALS at the virtual 2021 Annual Northeast ALS Meeting.
-
Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)
10/6/2021
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced positive Phase 1 clinical results and regulatory progress for two investigational small molecule therapeutics in development for the treatment of amyotrophic lateral sclerosis (ALS) at the 2021 Annual Northeast ALS (NEALS) Meeting.
-
BioSpace Movers & Shakers, Oct. 1
10/1/2021
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
9/29/2021
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced upcoming presentations at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting being held virtually, October 6-7.
-
Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer
9/27/2021
Denali Therapeutics Inc. today announced the appointment of Katie Peng to the newly created role of Chief Commercial Officer.
-
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS— Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS —
9/9/2021
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that dosing recently commenced in a Phase 1b study of DNL343, its brain-penetrant small molecule activator of EIF2B, in participants diagnosed with amyotrophic lateral sclerosis (ALS).
-
Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRNPreclinical studies show enhanced brain uptake of progranulin can be achieved using Denali’s Transport Vehicle to cross the blood-brain barrier
8/26/2021
Denali Therapeutics Inc. today announced publication of preclinical proof of concept for using its Protein Transport Vehicle (PTV) to enhance brain uptake of peripherally administered progranulin (PTV:PGRN).
-
Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
8/4/2021
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases, reported financial results for the second quarter ended June 30, 2021, and provided business highlights.
-
Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
7/25/2021
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases, announced additional positive interim data from a Phase 1/2 study evaluating ETV:IDS, an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system and peripheral manifestations of Hunter syndrome.
-
Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021Management to host webinar for analysts and investors on July 25th
7/15/2021
Denali Therapeutics Inc. today announced its participation at MPS 2021, the 16 th Annual International Symposium of MPS and Related Diseases
-
Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients
6/28/2021
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that its partner Sanofi has commenced dosing in a Phase 2 study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in patients with cutaneous lupus erythematosus (CLE).
-
Flagship Pioneering announced a massive cash infusion to support the development and launch of new companies aiming at various diseases and global health threats.
-
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
-
Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
5/3/2021
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2021, and provided business highlights.
-
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease
5/1/2021
Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease
-
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)
3/11/2021
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II).
-
Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights
2/25/2021
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the full year ended December 31, 2020 and provided business highlights.